- Agriculture
- Antibiotic/anti-viral
- Biologics
- Biomarkers
-
By Clinical Application
- Anesthesiology
- Blood & Lymphatic Disease
- CNS & Neurosciences
- Dermatology
- Diabetes, Metabolism, Endocrinology & Obesity
- Ear, Nose, & Throat
- Emergency Services
- Gastroenterology & Digestive Disease
- General & Plastic Surgery
- Health Education, Medical Training and Operations
- Heart and Vascular
- Immunology, Autoimmune & Inflammation
- Infectious Diseases
- Mental Health
- Multiple clinical applications
- Musculoskeletal Disorders, Orthopedics/Bone
- Nephrology/Renal
- Oncology
- Ophthalmology
- Orphan Diseases
- Pediatrics
- Physical Medicine & Rehabilitation
- Radiology
- Regenerative Medicine / Tissue Engineering
- Reproductive Health: Obstetrics & Gynecology
- Respiratory & Pulmonary
- Surgery
- Transplantation
- Urology
- Wound Healing
- COVID-19
- Creative Works
- Diagnostics
- Drug Delivery
- Drug screening and discovery
- Energy, Cleantech & Environmental
- Engineering & Physical Sciences
- Gene therapy
- Imaging
- Materials
- Medical Devices
- Nutraceuticals
- Other
- Research & Design Tools
- RNAi/siRNA
- Sensors & Controls
- Small molecules ×
- Software & Information Technology
- Stem Cells
- Vaccines
- Veterinary Medicine
Novel drugs for the treatment of dystonia
Value Proposition Dystonia is a classification of rare and debilitating movement disorders, for which there exists few therapeutic options. Treatments include therapy with botulinum neurotoxin to induce paralysis or deep brain stimulation. Not only are…
Improving immune checkpoint therapies for cancer by inhibiting the PCSK9 protein
Value Proposition Immune checkpoint inhibitor therapies are exciting new drugs for treatment of cancers. Despite their efficacy for certain cancers, immune checkpoint inhibitors only effective in 10-30% of cancer patients. Because of this, there is…
Beta-arrestin inhibition to prevent S1P1 internalization as a treatment for intracranial diseases
Value Proposition Glioblastomas (GBMs) are among the most common and deadly malignant brain tumors with a mean survival time of approximately 14-15 months following diagnosis. Current treatments for GBMs include surgery, radiation, and chemotherapy, however,…
A therapeutic formulation for preventing posttraumatic osteoarthritis after joint injuries
Value Proposition Osteoarthritis (OA) is an affliction of the joints that affects approximately 27 million people in the U.S . Posttraumatic osteoarthritis (PTOA), or osteoarthritis occuring after joint injury, accounts for approximately 12% of these…
Antimicrobial prochelators to target drug-resistant bacteria
Value Proposition According to the CDC, each year 2.8 million people in the United States develop an antibiotic-resistant infection, leading to more than 35,000 deaths. Beta lactams were the largest segment in the antibiotics market…
C-nitroso donors of neutral nitric oxide to treat hypertension and other diseases
Value proposition Hypertension, also known as high blood pressure, can lead to severe complications and increase the risk of heart disease, stroke, and death. About 1 out of 3 US adults, or about 75 million…
An effective FASN inhibitor
Value Proposition Many tumors are dependent on de novo fatty acid synthesis as a source of long chain fatty acids to maintain growth and interdicting at key steps in this pathway may have therapeutic benefit.…
Novel dystonia treatment drugs
Value Proposition Dystonia is a movement disorder characterized by sustained, often painful involuntary postures, causing motor disabilities and a marked decrease in quality of life. Dystonia is the third most common movement disorder behind Parkinson’s…
Chemical modulators of immune checkpoints and therapeutic use
Compounds and pharmaceutical compositions that down-regulate immune checkpoints such as PD-1, PD-L1 and CTLA-4 are provided. Also provided are methods of treating a disease by down-regulating immune checkpoints such as PD-1, PD-L1 and CTLA-4. The…
Conjugated neuroactive steroid compositions and methods of use thereof
The present disclosure provides modified neuroactive steroids. The modified neuroactive steroids may comprise, consist of, or consist essentially of a therapeutic agent and/or a modifying moiety. The modified neuroactive steroid can have modified characteristics as…
Compositions and methods for treating gram-negative bacterial infection
Value Proposition Antimicrobial resistance is considered to be one of the biggest crises facing modern medicine today. Without desperately needed intervention, it is estimated that by 2050 over 10 million deaths per year will be…
Methods and compositions for the identification of insect repellent compounds
Value Proposition Insect vector-borne infectious diseases are a major public health threat to both developing and industrialized nations. Though many insects may transmit disease, mosquitoes of of the Aedes and Anopheles genus are particularly known…